CTS Trials Network: A paradigm shift in the surgical treatment of moderate ischemic mitral regurgitation?

Area of Science:

• Cardiothoracic Surgery
• Cardiovascular Research
• Clinical Trials

Background:

• Moderate ischemic mitral regurgitation (IMR) is common in patients undergoing coronary artery bypass grafting (CABG).
• The optimal surgical strategy for moderate IMR remains controversial.
• Previous studies have yielded conflicting results regarding the benefit of mitral valve repair in this population.

Purpose of the Study:

• To evaluate the effect of mitral valve repair in addition to CABG on left ventricular remodeling at one year in patients with moderate IMR.
• To assess secondary clinical and echocardiographic endpoints in the same patient cohort.

Main Methods:

• A randomized trial involving 301 patients with moderate IMR undergoing CABG.
• Patients were assigned to either CABG alone or CABG with mitral valve repair.
• Primary endpoint was the change in left ventricular end-diastolic volume index (LVEDVI) at one year.

Main Results:

• The study reported one-year follow-up results from the Cardiothoracic Surgery Trials Network.
• Results indicated no significant benefit from mitral valve repair in addition to CABG for moderate IMR.
• Specific data on LVEDVI changes and secondary endpoints were presented.

Conclusions:

• The findings suggest that routine mitral valve repair may not be beneficial for patients with moderate ischemic mitral regurgitation undergoing CABG.
• The study contributes to the ongoing debate regarding the surgical management of moderate IMR.
• Further research may be needed to clarify the role of mitral repair in specific patient subgroups.